Research programme: oral film-based therapeutics - IntelGenx

Drug Profile

Research programme: oral film-based therapeutics - IntelGenx

Alternative Names: INT 0015/2008; INT 0037; INT 0037/2013; INT 0039/2013; INT 0040; INT 0040/2013; INT 0040/2014; INT 0041/2015; INT 0042/2015

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IntelGenx Corp.
  • Class Carbolines
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Mouth disorders

Highest Development Phases

  • Research Alzheimer's disease; Unspecified
  • No development reported Erectile dysfunction; Panic disorder

Most Recent Events

  • 28 Jun 2017 Topical oral film based products are available for licensing in USA as of 08 Jun 2017.
  • 08 Jun 2017 IntelGenx has patent protection for topical oral films, for the treatment of diseases of the oral mucosa using mucoadhesive particles
  • 27 Dec 2016 IntelGenx and Endo agree to co-develop and commercialise oral-film based therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top